On November 24, 2017, EQL announced that a license agreement has been entered into with a leading generic company for the license of EQL's product Potassium Chloride in Denmark, Norway and Finland. The agreement ran for three years and the reason for the out-licensing of Potassium Chloride was primarily that EQL at that time was not willing to tie up as much capital in stock as a launch of Potassium Chloride in these markets required. The license agreement was structured so that EQL received part of the profit from the sales of the product. When the agreement expired earlier this year, EQL chose to extend the agreement for Finland, but take back the rights for Denmark and Norway. This means that Potassium Chloride EQL Pharma 750mg prolonged-release tablets for the treatment of potassium deficiency, which EQL already offers in Sweden, will start to be sold in Denmark during the current quarter. Sales in Norway have not taken place during the license period and EQL is now evaluating that market for launch of the product.